Cite
HARVARD Citation
Markert, C. et al. (2014). CYP2C9 Polymorphism is not a Major Determinant of Bosentan Exposure in Healthy Volunteers. Clinical pharmacology & therapeutics. 95 (3), pp. 250-251. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Markert, C. et al. (2014). CYP2C9 Polymorphism is not a Major Determinant of Bosentan Exposure in Healthy Volunteers. Clinical pharmacology & therapeutics. 95 (3), pp. 250-251. [Online].